Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, and Ginkgo Bioworks announced a partnership to develop a bactofection platform to deliver RNA-based therapeutics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DNA:
- Ginkgo Bioworks expands R&D facilities
- Ginkgo Bioworks, Esperovax announce partnership to develop circular RNAs
- Ginkgo Bioworks, MoH of Botswana enter MoU on biosecurity capabilities
- Cronos unveils new CBC product, Spinach FEELZ Day Trip Gummies
- Berenberg starts ‘well-positioned’ disruptor Ginkgo Bioworks with a Buy